Beyond Air, Inc.
For the period ended Mar 31, 2026. Filed Jun 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 26, 2026
XAIR$2.29+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share data)
| Common Stock (1) · Treasury · Additional Paid-in · Accumulated · Accumulated Other Comprehensive · Non- Controlling · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Number · Amount · Stock · Capital · Deficit · Income/(Loss) · Interest · Equity | |||||||||
| Balance as of March 31, 2024 | 2,295,042 | $ | - | $(25) | $264,785 | $(239,697) | $(15) | $2,138 | $27,186 |
| Issuance of common stock – At The Market equity offering | 337,101 | - | - | 2,151 | - | - | - | 2,151 | |
| Sale of common stock and pre-funded warrants | 1,250,000 | - | - | 18,858 | - | - | - | 18,858 | |
| Issue of common stock warrants | - | - | - | 3,159 | - | - | - | 3,159 | |
| Issuance of common stock upon exercise of warrants | 234,156 | - | - | 365 | - | - | - | 365 | |
| Issuance of common stock upon vesting of restricted shares | 12,240 | - | - | - | - | - | - | - | |
| NeuroNos issuance of stock | - | - | - | 1,765 | - | - | 235 | 2,000 | |
| Stock-based compensation | - | - | - | 8,907 | - | - | 239 | 9,146 | |
| Other comprehensive loss | - | - | - | - | - | (45) | - | (45) | |
| Net loss | - | - | - | - | (46,625) | - | (1,854) | (48,479) | |
| Balance as of March 31, 2025 | 4,128,539 | $ | - | $(25) | $299,990 | $(286,322) | $(60) | $758 | $14,341 |
| Issuance of common stock – At The Market equity offering | 2,441,775 | 1 | - | 8,134 | - | - | - | 8,135 | |
| Issuance of common stock – 2025 Reverse Stock Split rounding | 46 | - | - | - | - | - | - | - | |
| Sale of common stock and pre-funded warrants | 524,990 | - | - | 4,500 | - | - | - | 4,500 | |
| Issue of common stock warrants | - | - | - | 1,183 | - | - | - | 1,183 | |
| Issuance of common stock upon exercise of warrants | 3,088,704 | - | - | 2,868 | - | - | - | 2,868 | |
| Issuance of common stock upon vesting of restricted shares | 8,630 | - | - | - | - | - | - | - | |
| Issuance of common stock for conversion of debt | 1,600,000 | - | - | 3,341 | - | - | - | 3,341 | |
| NeuroNos issuance of stock | - | - | - | 573 | - | - | 127 | 700 | |
| Stock-based compensation | - | - | - | 4,998 | - | - | 284 | 5,282 | |
| Other comprehensive gain | - | - | - | - | - | 194 | - | 194 | |
| Net loss | - | - | - | - | (33,249) | - | (1,085) | (34,334) | |
| Balance as of March 31, 2026 | 11,792,684 | $1 | $(25) | $325,587 | $(319,571) | $134 | $84 | $6,210 | |
| (1) | Prior period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, Organization and Business for details. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.